Ifosfamide

Generic Name: Ifosfamide

Brand Names: Ifex

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 3778-73-2

Unique Ingredient Identifier: UM20QQM95Y

Background: Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent.

Indication: Used as a component of various chemotherapeutic regimens as third-line therapy for recurrent or refractory germ cell testicular cancer. Also used as a component of various chemotherapeutic regimens for the treatment of cervical cancer, as well as in conjunction with surgery and/or radiation therapy in the treatment of various soft tissue sarcomas. Other indications include treatment of osteosarcoma, bladder cancer, ovarian cancer. small cell lung cancer, and non-Hodgkin's lymphoma.

Associated Conditions: Bladder Cancer, Cervical Cancer, Ewing's Sarcoma, Head And Neck Cancer, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma (NHL), Osteosarcoma, Ovarian Cancer, Pancreatic Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Testicular Germ Cell Cancer, Thymoma

Associated Therapies: -

Clinical Trials

Combination Chemotherapy Followed by Stem Cell Transplant and Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

Not Applicable

Conditions: Neuroblastoma

First Posted Date: 2007-09-10

Last Posted Date: 2015-07-16

Lead Sponsor: German Society for Pediatric Oncology and Hematology GPOH gGmbH

Target Recruit Count: 360

Registration Number: NCT00526318

Locations: 🇩🇪
Klinikum Augsburg, Augsburg, Germany
🇩🇪
Evangelisches Krankenhauus Bielfeld, Biefeld, Germany
🇩🇪
Klinikum Duisburg, Duisburg, Germany

and more 64 locations

Neoadjuvant Chemotherapy for Patients With Squamous Cell Carcinoma of the Penis

Phase 2

Completed

Conditions: Penile Cancer

Interventions: Drug: Ifosfamide
Drug: Paclitaxel (Taxol)
Drug: Cisplatin

First Posted Date: 2007-08-07

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 30

Registration Number: NCT00512096

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Topotecan, Ifosfamide and Carboplatin in Children and Young Adults With Solid Tumors

Phase 1

Completed

Conditions: Solid Tumors

Interventions: Drug: Topotecan
Drug: Ifosfamide
Drug: Carboplatin

First Posted Date: 2007-07-18

Last Posted Date: 2012-08-01

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 2

Registration Number: NCT00502892

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients

Phase 2

Completed

Conditions: Lymphoma

Interventions: Drug: Etoposide
Drug: G-CSF
Drug: GM-CSF
Drug: Isophosphamide
Drug: Rituximab
Procedure: Apheresis

First Posted Date: 2007-07-11

Last Posted Date: 2013-08-02

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 84

Registration Number: NCT00499343

Locations: 🇺🇸
U.T.M.D. Anderson Cancer Center, Houston, Texas, United States

Ifosfamide and Doxorubicin in Patients With Refractory Nasopharyngeal Carcinoma

Phase 2

Terminated

Conditions: Refractory Nasopharyngeal Carcinoma

Interventions: Drug: Ifosfamide
Drug: Doxorubicin

First Posted Date: 2007-06-11

Last Posted Date: 2019-02-11

Lead Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Target Recruit Count: 9

Registration Number: NCT00484601

Locations: 🇸🇬
Johns Hopkins Singapore International Medical Center, Singapore, Singapore

Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors

Phase 2

Completed

Conditions: Brain and Central Nervous System Tumors
Extragonadal Germ Cell Tumor
Ovarian Cancer
Teratoma
Testicular Germ Cell Tumor

Interventions: Biological: pegfilgrastim
Drug: cisplatin
Drug: ifosfamide
Drug: paclitaxel

First Posted Date: 2007-05-07

Last Posted Date: 2017-11-28

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 60

Registration Number: NCT00470366

Locations: 🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸
USC/Norris Comprehensive Cancer Center and Hospital, Los Angeles, California, United States

Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Phase 3

Active, not recruiting

Conditions: Sarcoma

Interventions: Drug: cisplatin
Drug: doxorubicin hydrochloride
Drug: etoposide
Drug: ifosfamide
Drug: methotrexate
Drug: zoledronic acid
Procedure: conventional surgery

First Posted Date: 2007-05-07

Last Posted Date: 2024-04-18

Lead Sponsor: UNICANCER

Target Recruit Count: 318

Registration Number: NCT00470223

Locations: 🇫🇷
Centre Jean Perrin, Clermont-Ferrand, France
🇫🇷
CHR de Besancon - Hopital Saint-Jacques, Besancon, France
🇫🇷
CHU Hopital A. Morvan, Brest, France

and more 34 locations

Combination Chemotherapy in Treating Young Patients With Recurrent or Resistant Malignant Germ Cell Tumors

Phase 2

Completed

Conditions: Childhood Extracranial Germ Cell Tumor
Childhood Malignant Ovarian Germ Cell Tumor
Childhood Malignant Testicular Germ Cell Tumor
Ovarian Yolk Sac Tumor
Recurrent Childhood Malignant Germ Cell Tumor
Testicular Mixed Choriocarcinoma and Yolk Sac Tumor
Ovarian Embryonal Carcinoma
Recurrent Malignant Testicular Germ Cell Tumor
Ovarian Choriocarcinoma
Recurrent Ovarian Germ Cell Tumor

Interventions: Drug: Carboplatin
Biological: Filgrastim
Drug: Ifosfamide
Other: Laboratory Biomarker Analysis
Drug: Paclitaxel

First Posted Date: 2007-04-27

Last Posted Date: 2018-08-29

Lead Sponsor: Children's Oncology Group

Target Recruit Count: 20

Registration Number: NCT00467051

Locations: 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸
Children's National Medical Center, Washington, District of Columbia, United States
🇺🇸
Palmetto Health Richland, Columbia, South Carolina, United States

and more 92 locations